PMC:7507645 / 5369-5699 JSONTXT

{"project":"TEST0","denotations":[{"id":"32958075-228-234-1506673","span":{"begin":326,"end":328},"obj":"[\"29171818\"]"}],"text":"Eligible patients were randomized 1:1:1 to receive subcutaneous injections of either fremanezumab quarterly (675 mg of fremanezumab at baseline and placebo at weeks 4 and 8), fremanezumab monthly (675 mg of fremanezumab at baseline and 225 mg at weeks 4 and 8), or placebo (matching placebo at baseline and at weeks 4 and 8) [16]."}

{"project":"2_test","denotations":[{"id":"32958075-29171818-60560880","span":{"begin":326,"end":328},"obj":"29171818"}],"text":"Eligible patients were randomized 1:1:1 to receive subcutaneous injections of either fremanezumab quarterly (675 mg of fremanezumab at baseline and placebo at weeks 4 and 8), fremanezumab monthly (675 mg of fremanezumab at baseline and 225 mg at weeks 4 and 8), or placebo (matching placebo at baseline and at weeks 4 and 8) [16]."}